Purpose Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving
surgery (BCS) for estrogen receptor (ER)–positive breast cancer. To study this treatment
option, responses to three AIs were compared in a randomized phase II neoadjuvant trial
designed to select agents for phase III investigations. Patients and Methods Three hundred
seventy-seven postmenopausal women with clinical stage II to III ER-positive (Allred score 6-
8) breast cancer were randomly assigned to receive neoadjuvant exemestane, letrozole, or …

Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and
exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast
cancer : clinical and biomarker outcomes and predictive value of the baseline PAM50-based
intrinsic subtype-ACOSOG Z1031 | CiNii Research … Randomized phase II neoadjuvant
comparison between letrozole, anastrozole, and exemestane for postmenopausal women
with estrogen receptor-rich stage 2 to 3 breast cancer : clinical and biomarker outcomes and …